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Abstract
Insulin is as a major postprandial hormone with profound effects on carbohydrate, fat, and protein metabolism. In the
absence of exogenous insulin, patients with type 1 diabetes exhibit a variety of metabolic abnormalities including
hyperglycemia, glycosurea, accelerated ketogenesis, and muscle wasting due to increased proteolysis. We analyzed plasma
from type 1 diabetic (T1D) humans during insulin treatment (I+) and acute insulin deprivation (I-) and non-diabetic
participants (ND) by
1H nuclear magnetic resonance spectroscopy and liquid chromatography-tandem mass spectrometry.
The aim was to determine if this combination of analytical methods could provide information on metabolic pathways
known to be altered by insulin deficiency. Multivariate statistics differentiated proton spectra from I- and I+ based on several
derived plasma metabolites that were elevated during insulin deprivation (lactate, acetate, allantoin, ketones). Mass
spectrometry revealed significant perturbations in levels of plasma amino acids and amino acid metabolites during insulin
deprivation. Further analysis of metabolite levels measured by the two analytical techniques indicates several known
metabolic pathways that are perturbed in T1D (I-) (protein synthesis and breakdown, gluconeogenesis, ketogenesis, amino
acid oxidation, mitochondrial bioenergetics, and oxidative stress). This work demonstrates the promise of combining
multiple analytical methods with advanced statistical methods in quantitative metabolomics research, which we have
applied to the clinical situation of acute insulin deprivation in T1D to reflect the numerous metabolic pathways known to be
affected by insulin deficiency.
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Introduction
Insulin is a pivotal hormone regulating the metabolism of key
macronutrients such as carbohydrate, fat, and protein to maintain
metabolic homeostasis. Insulin deficiency induces a variety of
metabolic derangements in type 1 diabetes. Elevated plasma
glucose, ketones, free fatty acids, and branched-chain amino acids
(BCAA) are hallmarks of untreated type 1 diabetes [1,2,3].
Underlying metabolic pathways that contribute to these effects
include increased hepatic gluconeogenesis [4], increased glycogen-
olysis[5],increased fluxthroughtheglucose-alanineandCoricycles
[6,7], increased protein breakdown in skeletal muscle [8,9,10,11],
and increased splanchnic protein synthesis [9]. Insulin treatment
ameliorates the catabolic state in type 1 diabetic people [9,12].
We recently studied C-peptide-negative type 1 diabetic subjects
while treated with insulin and again during acute insulin
deprivation (8 hours) [13]. We found that insulin deficiency
altered skeletal muscle bioenergetics, as evidenced by significantly
reduced skeletal muscle mitochondrial ATP production capacity
and decreased transcript levels of several genes involved in
mitochondrial function [13]. This study recapitulated a new role
for insulin as a regulator of skeletal muscle mitochondrial function.
In another report from the same cohort of patients, we report that
insulin treatment and deprivation induced significant changes in
the synthesis rates of individual plasma proteins, which are mostly
synthesized in the liver [14]. In the present study, we measured the
concentrations of plasma biomolecules in this well-characterized
cohort using proton magnetic resonance spectroscopy (
1H-MRS)
and liquid chromatography tandem mass spectrometry (LC-MS/
MS). Our objective was to illustrate the utility of a combination of
analytical methods and multivariate statistical analysis for
detecting a metabolic fingerprint that reflects known pathways
that are altered with disease. Herein we apply this to the clinical
situation of acute insulin deprivation in a cohort of type 1 diabetic
patients in whom we have previously characterized several altered
metabolic pathways [13,14].
Results
Contrasting insulin treatment and deprivation in type 1
diabetes
We obtained plasma samples from 7 c-peptide negative type 1
diabetic individuals (T1D) and 7 non-diabetic controls (Con) that
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10538were matched for age (T1D=31.162.9 yrs, Con=30.263.4 yrs),
body mass (T1D=80.264.7kg, Con=81.967.4 kg) and BMI
(T1D=26.561.2 kg/m
2, Con=25.261.3 kg/m
2). Type 1 dia-
betic people were studied while treated with insulin and also after
8 hours of insulin deprivation. We performed metabolic profiling
of plasma samples using a combination of
1H-NMR and an LC-
MS/MS based method to measure plasma amino acid metabolite
concentrations. We observed the expected elevations in plasma
glucose (,4 fold), beta-hydroxybutyrate (,5 fold), acetone (,9
fold), and acetoacetate (,40 fold) in insulin deprived individuals
compared to the insulin treated state and non-diabetic controls
(Table 1). We previously reported that urinary nitrogen excretion
rate increased over 8 hours of insulin deprivation in these
individuals, however at the 8 hour time point, ammonia levels in
plasma and urine were 16% and 70% lower, respectively, in
insulin deprived compared to insulin treated and control subjects
(Table 2). Plasma 3-methylhistidine levels, a marker of skeletal
muscle protein degradation, were similar across all groups
(Table 2).
Evidence of altered protein metabolism revealed by LC-
MS/MS analyses of plasma
We profiled physiological amino acids and amino acid
metabolites in plasma samples using a LC-MS/MS method with
Waters MassTrack Amino Acid Analysis Solution (Waters,
Milford, MA). We monitored the concentrations of 44 metabolites,
of which 41 were reliably detected in all samples, including all 20
standard amino acids (Supplemental material, Figure S1).
Absolute quantitation was performed using a set of amino acid
standards including glutamine, tryptophan, allo-isoleucine, and
norvaline. The reproducibility of the LC-MS/MS approach for
measuring amino acids and amino acid metabolites was found to
be high (average CV=9.5%, see Table S1, supplemental
materials) based on repeated measurements over a 1-month
period using a plasma quality control sample (N=19 replicates).
We found that insulin deprivation significantly (P,0.05) increased
the levels of 5 amino acids (leucine ,2 fold, isoleucine ,2 fold,
valine ,1.6 fold, phenylalanine ,1.2 fold, tyrosine ,1.1 fold,
Table 2) and significantly decreased the levels of 3 amino acids
(glycine ,1.3 fold, glutamate ,1.3 fold, threonine ,1.1 fold,
Table 2), while the remaining 12 amino acids were unchanged
compared to the same individuals treated with exogenous insulin
and non diabetic controls (Table 2). Twenty-one additional amino
acid metabolites were detected and quantified, of which 5
significantly increased and 1 significantly decreased with insulin
deprivation (Table 2).
Spectral profile of treated and uncontrolled type 1
diabetes
Plasma samples were also analyzed by
1H nuclear magnetic
resonance spectroscopy. Fourteen plasma metabolites were
identified based on their characteristic chemical shifts and
multiplicities [15] (Supplemental material, Figure S2) and
quantified by integrating peak areas relative to a reference signal
from 3-(Trimethylsilyl)propionic acid-d4 sodium salt (TSP). These
NMR analyses revealed the expected elevations in plasma glucose
and ketone levels with insulin deprivation (Table 1). Although the
majority of the measured metabolites were unique to each
analytical technique, there were 4 amino acid metabolites that
were measured in common with LC-MS/MS and
1H-NMR
(valine, alanine, tyrosine, histidine, tables 1 and 2). Both methods
revealed similar trends when comparing insulin treated and
deprived type 1 diabetic people and non-diabetic controls. In
agreement with the LC-MS/MS data, NMR analyses indicated
elevated branched-chain amino acid (valine ,1.6 fold) concen-
trations with insulin deprivation, but no change in several other
amino acids (alanine, tyrosine, histidine) (Table 1).
Several metabolites involved in cellular energy metabolism were
measured by
1H - M R S( e . g . ,a c e t a t e ,f o r m a t e ,c i t r a t e ,c r e a t i n i n e ,
lactate). Of these metabolites, only acetate exhibited elevated levels in
insulin-deprived type 1 diabetic individuals (Table 1). Allantoin, a
product of nonenzymatic urate oxidation, was significantly elevated
Table 1. Micromolar concentrations of plasma metabolites measured by
1H magnetic resonance spectroscopy.
T1D T1D Control P P P
(insulin treated) (insulin deprived) (non-diabetic)
treated v.
deprived
treated v.
control
control v.
deprived
Glucose (mM) 6.461.3 22.562.0 5.761.1 ,0.0001 0.809 ,0.0001
Allantoin 4.063.4 9.461.0 4.662.7 0.017 0.809 0.014
Valine 160.5637.8 242.8651.3 172.6636.4 0.004 0.809 0.026
b-hydroxybutyrate 93.06141.5 1392.16834.2 68.66128.3 0.017 0.809 0.014
Acetone 99.3652.1 757.26421.8 75.7646.5 0.017 0.809 0.014
Acetoacetate 26.3614.8 205.46126.5 23.5617.4 0.021 0.809 0.021
Acetate 41.969.2 69.5621.2 33.3614.3 0.026 0.809 0.014
Formate 14.8 62.0 12.964.0 13.462.7 0.459 0.809 0.841
Citrate 95.7634.9 123.8657.4 106.3657.3 0.459 0.809 0.737
Alanine 277.16115.6 233.4648.1 264.9660.0 0.535 0.809 0.468
Tyrosine 33.6611.2 32.166.7 27.7610.9 0.901 0.809 0.542
Creatinine 46.368.9 47.9611.5 48.7614.7 0.901 0.809 0.915
Lactate 427.46173.4 435.96116.2 361.7667.2 0.986 0.809 0.306
Histidine 83.767.7 83.8614.5 88.0619.1 0.987 0.809 0.762
Data are presented as means6SEM. P values reflect Benjamini–Hochberg correction.
doi:10.1371/journal.pone.0010538.t001
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insulin is withdrawn from patients with type 1 diabetes (Table 1).
Multivariate statistical analysis differentiates plasma
based on metabolites other than glucose
The NMR data were further analyzed by principal component
analysis (PCA) using the full, processed
1H NMR spectra with
glucose regions removed to differentiate the plasma of insulin-
deprived type 1 diabetic people from insulin-treated T1D and
non-diabetic controls. The PCA score plots of PC1 versus PC2
revealed that data points, each representing the
1H spectrum of a
single participant, were clustered in a way that allowed insulin-
deprived T1D to be clearly differentiated from insulin-treated
T1D and controls along principal component 1 (PC1, Figure 1a).
Table 2. Micromolar concentrations of 20 standard amino acids (top panel) and amino acid metabolites (bottom panel) measured
by LC-MS/MS.
T1D T1D Control P P P
(insulin treated) (insulin deprived) (non-diabetic) treated v. deprived treated v. control control v. deprived
Valine 189.4614.5 303.5628.2 213.5611.8 0.003 0.616 0.078
Leucine 106.369.7 210.1620.3 117.666.5 0.005 0.743 0.010
Isoleucine 52.263.5 114.1613.0 58.564.1 0.005 0.653 0.010
Phenylalanine 38.161.1 44.162.1 42.461.4 0.031 0.403 0.759
Glutamate 113.3620.3 88.7618.5 108.4630.2 0.039 0.899 0.805
Glycine 200.6612.4 150.0620.7 193.2621 0.062 0.862 0.516
Tyrosine 46.063.6 52.061.7 45.063.3 0.064 0.899 0.417
Cystine 13.566.8 13.066.8 21.466.4 0.201 0.747 0.678
Threonine 95.264.1 87.469.6 121.3612.1 0.659 0.462 0.351
Glutamine 337.9632.9 310.5636.2 399.7641.1 0.659 0.653 0.489
Serine 88.968.0 80.166.6 93.463.5 0.659 0.832 0.417
Histidine 62.061.7 63.164.3 68.468.4 0.659 0.747 0.805
Tryptophan 33.662.3 37.664.3 31.762.4 0.659 0.832 0.603
Asparagine 36.064.0 34.065.5 43.161.8 0.659 0.468 0.417
Alanine 229.4622.6 212.7622.5 219.5615.5 0.759 0.849 0.955
Arginine 67.266.8 72.969.0 82.466.0 0.775 0.468 0.678
Lysine 147.567.0 149.8611.8 151.565.5 0.971 0.849 0.979
Proline 145.969.3 147.969.5 140.769.9 0.971 0.849 0.805
Methionine 14.061.1 13.862.0 16.260.8 0.971 0.468 0.603
Aspartate 6.560.9 6.461.3 5.461.0 0.971 0.747 0.759
a-aminoadipic acid 0.760.1 1.360.2 0.960.1 0.020 0.403 0.273
B-aminoisobutyate 1.460.2 2.060.2 2.560.4 0.033 0.403 0.603
Ornithine 43.563.1 52.664.3 47.763.6 0.049 0.747 0.678
a-amino-N-butyrate 23.661.6 31.962.1 25.761.2 0.052 0.736 0.156
Ammonia 121.0618.6 100.4617.2 109.3628.9 0.088 0.856 0.955
Cystathionine 1 0.0760.04 0.1860.08 0.1860.04 0.090 0.460 0.991
Hydroxyproline 7.960.5 6.460.7 6.560.4 0.224 0.460 0.979
Taurine 35.061.9 37.461.8 39.461.4 0.224 0.462 0.678
B-alanine 2.960.3 2.760.3 2.660.2 0.333 0.747 0.979
1-Methylhistidine 21.066.4 20.466.4 16.263.1 0.659 0.747 0.766
Allo-isoleucine 0.960.1 1.060.3 0.860.1 0.659 0.747 0.678
Hydroxylysine-2 0.7060.04 0.6660.05 0.7860.04 0.659 0.616 0.417
Hydroxylysine-1 0.3460.02 0.3260.03 0.3360.02 0.659 0.849 0.979
3-Methylhistidine 4.860.6 4.760.6 4.760.4 0.659 0.899 0.991
Citrulline 26.962.2 25.961.8 28.462.0 0.795 0.843 0.678
Ethanolamine 6.460.4 6.460.3 7.561.4 0.795 0.747 0.759
Sarcosine 1.160.1 1.060.2 1.160.2 0.759 0.899 0.910
c-amino-N-butyrate 0.1260.01 0.1160.01 0.1360.01 0.947 0.616 0.524
Phosphoethanolamine 0.2960.16 0.2960.20 0.6160.12 0.957 0.489 0.516
Data are presented as means6SEM. P values reflect Benjamini–Hochberg correction.
doi:10.1371/journal.pone.0010538.t002
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(Figure 1b1) and aromatic region (Figure 1b2) indicate that
ketones, lactate, and allantoin strongly contribute to the separation
of NMR spectra from the different groups along PC1. The PCA
analyses were performed after removing the glucose regions to
allow differentiation of spectra without the overriding influence of
the strong glucose signals.
The integration of NMR and MS data using correlation
matrices
We generated correlation matrices for the plasma metabolites
measured by both MS and NMR to create a compendium
metabolic profile that integrates the complementary information
from the two analytical methods. For metabolites measured in
common by both NMR and MS, correlation matrices included
data measured by NMR. Separate correlation matrices were
created for insulin treated T1D (Figure 2a) and insulin deprived
T1D (Figure 2b). The correlation plots reveal a wide range of
correlation coefficients among all of the measured metabolites,
ranging from 1.0 (maximum positive correlation) to 21.0
(maximum anticorrelation) and 0 indicating no correlation.
Figures 2a and 2b illustrate that several high positive (red, yellow
regions) or negative (blue regions) correlations were observed
among several metabolites during conditions of insulin treatment
and deprivation in the same T1D individuals. It is of interest to
determine which correlations between specific metabolites were
significantly altered by the presence or absence of insulin. This
information can be gleaned from a side-by-side comparison of the
two correlation plots (Figures 2a and 2b) or, more easily, from the
correlation difference matrix generated in Figure 3. Pixels colored
red or yellow indicate that the correlation coefficient between two
metabolites became less positive or more negative with insulin
treatment compared to insulin deprivation. Conversely, dark blue
pixels represent a shift toward more positive correlation between
two metabolites with insulin treatment compared to insulin
deprivation. From the correlation difference matrix, it is apparent
that the ketone levels (acetoacetate, 3-hydroxybutyrate, acetone)
were positively correlated with plasma lactate during insulin
Figure 1. Scores plot (a) and PC1 loadings plot (b1 and b2) from the PCA of
1H NMR spectra of plasma from insulin deprived
patients, treated patients and healthy people (glucose and residual water peaks were removed prior to PCA). Intensities of the NMR
variables were normalized using the total sum of intensities. The data were analyzed after being mean-center scaled. Identified metabolites: 1,
allantoin; 2, acetate; 3, acetone; 4, 3-hydroxybutyrate ; 5, acetoacetate; 6, valine; 7, lactate; 8, alanine; 9, tyrosine; 10, citrate; 11, histidine; 12, formate;
13, creatinine; 14, glycoprotein N-acetyl groups; 15, lipid:CH3; 16, lipid:CH2; 17, lipid:CH2CH2-CO;18, lipid:CH2-C=C;19, Lipid:fatty acyl groups=CH.
doi:10.1371/journal.pone.0010538.g001
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treatment. Similarly, ketones were also positively correlated with
several amino acids such as tyrosine, valine, leucine, and
phenylalanine during insulin deprivation, but this correlation
became negative with insulin treatment. Citrate, another metab-
olite related to cellular energetics, was negatively correlated with
glutamate during insulin deprivation but the relationship between
these two metabolites became positive with insulin treatment.
During insulin deprivation, elevated allantoin was positively
correlated with ketones, acetate, creatinine, and lysine, but
negatively correlated with serine, arginine, glycine, and aspartate.
These relationships were largely reciprocal with insulin treatment.
Figure 2. Pearson’s correlations of the quantities of the 48 plasma metabolites measured by LC-MS/MS and
1H-NMR in type 1
diabetics who were insulin treated (a) or insulin deprived (b).
doi:10.1371/journal.pone.0010538.g002
Figure 3. The difference in correlation of the quantities of the 48 metabolites measured by LC-MS/MS and
1H-NMR between type 1
diabetics during insulin deprivation and insulin treatment.
doi:10.1371/journal.pone.0010538.g003
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Technological advances within the past 10 years have fueled the
rapid emergence of the field of metabolomics [15]. Analytical
methods such as nuclear magnetic resonance spectroscopy and
mass spectrometry are capable of measuring the concentrations of
a large number of metabolites from body fluids, allowing potential
disease biomarkers and altered biochemical pathways to be
identified [16,17,18,19]. Metabolomics has recently provided
insights into altered metabolic pathways in diabetes induced by
streptozotocin exposure in rats [6]. Specific metabolic derange-
ments linked, in part, to altered gut microbial metabolism were
revealed through the use of correlation matrices and multivariate
statistics. In humans, metabolomics has recently been used to link
serum metabolite profiles to clinical phenotypes and complications
of type I diabetes [20] and to identify early biomarkers to predict
the onset of the disease [21,22]. While it is currently known that
insulin deficiency in T1D has profound effects on many metabolic
pathways, the use of large scale metabolic profiling in revealing
these altered networks has not been fully explored in humans. In
this study, we analyzed plasma from type 1 diabetic humans in an
insulin-treated state and after withdrawing insulin for 8 hours and
non-diabetic controls. We quantified several plasma metabolites
using
1H NMR and amino acid metabolites by LC-MS/MS. This
complementary analytical information was paired with multivar-
iate statistical methods to highlight several metabolic networks
known to be altered in untreated type 1 diabetes.
The
1H-NMR analyses revealed elevated plasma glucose,
ketones, and branched-chain amino acids (BCAA), which are
well-known hallmarks of insulin deficiency in type 1 diabetes [2,3].
We anticipated that lactate and alanine would be elevated in the
plasma of insulin-deprived individuals, consistent with increased
gluconeogenesis through the glucose-alanine and Cori cycles as
previously shown in diabetic rats [6] and humans [7]. In contrast,
we found that plasma alanine was similar in insulin deprived
compared to treated T1D. We also found modest, non-significant
increases in plasma lactate with insulin deprivation. Notwithstand-
ing, principal component analysis revealed that lactate was a
strong contributor to differentiation of plasma from insulin treated
and insulin deprived type 1 diabetic individuals. These data
preclude any definitive conclusions concerning the involvement of
the Cori cycle or glucose-alanine cycle.
We find that branched chain amino acids are elevated in plasma of
untreated T1D, consistent with previous reports [1,2]. Elevated
BCAA are generally attributed to increased muscle protein
breakdown and release of amino acids from muscle proteins
[10,23,24] and liver [9]. We were surprised to find that after 8 hours
ofinsulindeprivation,plasmaammonia levels(measured byLC-MS/
MS) showed a trend (p=0.088) toward lower levels in insulin-
deprived vs. treated T1D, even though these patients exhibited
greater urinary nitrogen loss over the first 6 hours of insulin
deprivation [13]. There are several probable explanations for this
finding. First, it is likely that transamination-deamination and
reamination occur during acute insulin deficiency and some nitrogen
is spared by synthesis of gluconeogenic precursors (e.g., alanine,
glutamine) from amino acid precursors such as alpha-ketoglutarate.
Our data do not support this possibility, since neither glutamine or
alanine levels differed with insulin deprivation or treatment. Second,
it is possible that increased urea cycle flux may buffer the appearance
of ammonia in the blood by detoxifying ammonia that would
otherwise accumulate as a by-product of amino acid catabolism.
Citrulline and ornithine are non-proteinogenic amino acids that are
involved in the urea cycle. Although citrulline levels did not differ
between I+ and I2, ornithine levels were higher in I2 vs. I+,m a k i n g
it difficult to ignore the possibility that increased urea cycle flux may
temper
the increase in plasma ammonia levels during acute insulin
deprivation.
We found that plasma 3-methylhistidine (3-MH) levels were
similar in insulin treated and deprived T1D, suggesting that
myofibrillar protein degradation is not likely to be affected by
short-term insulin deprivation. The urinary excretion of 3-MH is
commonly used as an index of the rate of muscle proteolysis when
subjects are eating a meat-free diet [25]. Although the subjects in
the present study were not on a meat-free diet, they were given a
weight-maintaining diet (carbohydrate:protein:fat=55:15:30%)
for three days prior to the study and remained in the fasting state
after a standard meal at 16:00 hours on evening prior to the study
day. This dietary control would minimize any dietary differences
across the conditions that could confound the interpretation of 3-
MH levels as a marker of muscle protein breakdown. One
potential caveat is that our interpretation of 3-MH is based on net
concentrations measured in the plasma, which provides no
information regarding its appearance and disappearance. How-
ever, since 3-MH is not reutilized in vivo and renal function is
normal, its excretion in urine reflects myofibrillar degradation with
minimal contribution from gut. The absence of any increase in
plasma 3-MH with insulin deprivation suggests that myofibrillar
protein degradation is not likely affected by short-term insulin
deprivation. Thus, the robust increase in muscle protein
degradation that has been documented during short-term insulin
deprivation [9] may represent non-myofibrillar muscle proteins.
In spite of a fairly comprehensive understanding of the effects of
diabetes on carbohydrate metabolism, much less is known about
the impact of this disease on protein metabolism. In this study, we
used LC-MS/MS to measure the abundance of plasma amino
acids and amino acid metabolites, which reflect the balance
between AA uptake and release by various tissues that are
influenced by changes in protein metabolism in response to the
presence or absence of insulin and ketone levels. Numerous
simultaneous processes will influence the plasma amino acid
profile during insulin deprivation and insulin treatment. First,
insulin acutely regulates gluconeogenesis by direct effects on amino
acid balance across the splanchnic bed [26]. Second, insulin
regulates protein synthesis and breakdown [8,9,10,11]. We
recently measured the individual synthesis rates of 41 plasma
proteins during insulin treatment and deprivation in T1D in this
cohort of participants [14]. This study demonstrated that the
synthesis rates of some plasma proteins were increased with insulin
deprivation while others decreased or did not change. Other
studies indicate that some amino acids are released by skeletal
muscle and taken up by the splanchnic region in response to
insulin deprivation [9]. Third, plasma amino acid levels are also
influenced by peripheral oxidation, particularly BCAA, which are
mainly oxidized in skeletal muscle [4]. Indeed, the plasma levels of
BCAA are often proposed as indices of metabolic control in type 1
and type 2 diabetes [2,27]. Furthermore, high ketone levels also
inhibit hepatic gluconeogenesis, stimulate splanchnic protein
synthesis, and may or may not inhibit muscle protein degradation
[28,29]. Taken together, there are many concurrent physiological
processes that are influenced by the presence or absence of insulin
that can impact plasma amino acid levels. In this study, we used a
relatively straightforward LC-MS/MS method to generate a
profile of plasma amino acids that is characteristic of the net effect
of many processes that are altered during insulin deprivation.
Parallel measurements by
1H-NMR revealed several changes in
plasma metabolites that are distinct and complementary to the
plasma amino acid metabolite profile measured by LC-MS/MS
Metabolomics in Diabetes
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to use the
1H-NMR data to differentiate plasma from T1D who were
either insulin treated or insulin deprived (Figure 1). Spectra from
insulin treated vs. insulin deprived T1D were differentiated by PCA
based largely on elevated ketones, lactate, and allantoin levels in
deprived patients. Acetate levels were also significantly elevated in
insulin-deprived T1D patients, although did not contribute substan-
tially to PCA loading plots. Compilation of information from PCA,
correlation matrices, and individual metabolite levels reveal a profile
of altered bioenergetics, which is consistent with impaired mitochon-
drial function in the absence of insulin that we have previously
reported in these individuals[13]. Original observations inthis cohort
of people indicate that insulin deprivation decreases mitochondrial
ATP production [13]. Furthermore, gene array studies showed that
insulin deprivation also decreased the transcript levels of genes
involved in oxidative phosphorylation, which was validated by RT-
PCR-based measurements of cytochrome c oxidase and ATP
synthase, and mitochondrial transcription factor A [13]. Impairments
at one or more levels of oxidative phosphorylation would be expected
to substantially alter the redox state of the mitochondria, effectively
slowing the entry of acetyl CoA into the tricarboxylic acid cycle and
potentially leading to accumulation of cytosolic acetyl CoA. This
effectiscompounded bytheconversionofcitrateto acetylCoA bythe
enzyme ATP citrate lyase [30]; an effect that is likely to contribute to
the NMR-observable increases in plasma acetate. Plasma lactate
levels were not significantly different in I+ and I2, but PCA revealed
lactate as an important factor that contributed to the metabolic
differentiation of I+ and I2. Although lactate is an important
mitochondrial substrate and gluconeogenic precursor [31], its
accumulation in plasma is a reflection of an imbalance between
energy demand and supply by the mitochondria. There are several
potential factors that are likely to explain elevated plasma lactate in
response to insulin deprivation. First, lactate may accumulate as a
result of decreased entry of acetyl CoA into the TCA cycle due to
impaired mitochondrial ATP synthesis, which was demonstrated in
these individuals [13]. Second, the conversion of pyruvate to acetyl
CoA is likely decreased under these conditions due to the absence of
insulin’s effect on activating pyruvate dehydrogenase. Others have
demonstrated increased urine lactate levels and TCA cycle
disturbances in rats treated with streptozotocin [6].
As previously reported in a rat model of T1D [6], we observed
increased plasma acetate during acute insulin deprivation. Several
factors may contribute to rising acetate levels with insulin
deprivation, including 1) impaired mitochondrial substrate
oxidation, 2) induction of acetyl-CoA synthetase 2 under ketogenic
conditions [32], 3) increased acetate release from the liver [32],
and 4) a defective acetate switch and exogenous acetate
production by gut microbes [6]. We did not observe significant
correlations among acetate, lactate, or other metabolites (ethanol,
succinate, formate) that would indicate a bacterial origin of acetate
[33]. Notwithstanding, the notion of microbial origin of many
plasma metabolites that are differentially elevated in controlled vs.
uncontrolled diabetes should not be excluded and awaits further
investigation.
Increased oxidative stress is a well-documented hallmark of
diabetes and hyperglycemia [6,33,34]. The elevated plasma
allantoin in insulin deprived T1D in the present study is consistent
with this notion, as allantoin reflects non-enzymatic uric acid
oxidation and is used as a biomarker of oxidative stress in humans
[35]. Oxidative stress during insulin deprivation appears to be due,
in part, to activation of NADPH oxidase and uncoupling of
endothelium nitric oxide synthase [36]. However, it is also possible
that mitochondrial dysfunction may be a determinant of increased
oxidative stress during acute insulin deprivation. Mitochondrial
superoxide formation is largely dependent on the mitochondrial
membrane potential (Dy), which would be expected to be elevated
when ATP synthesis is impaired in the presence of excess
substrate. In support of this notion, others have found that
hyperglycemia increases superoxide production in endothelial cells
by oversupply of respiratory chain reducing equivalents and
elevated Dy [37]. In sum, allantoin represents a convenient
biomarker of oxidative stress due to its appearance in the
1H-
NMR spectrum of human plasma and illustrates how insulin
deprivation provokes oxidative stress, possibly by increasing the
rate of superoxide production as a consequence of decreased
mitochondrial phosphorylation activity.
By coupling the high sensitivity and specificity of MS with
highly quantitative and reproducible nature of NMR spectrosco-
py, it is possible to perform more comprehensive metabolic
profiling than allowed by each analytical method alone. In the
current study, we integrated information from the two distinct
analytical methods with multivariate statistical analyses to generate
a plasma metabolite profile that is characteristic of several
underlying physiological processes that are known to be altered
by short-term insulin deprivation in type 1 diabetic people (e.g.,
mitochondrial dysfunction, oxidative stress, protein synthesis,
degradation, and oxidation, gluconeogenesis, and ketogenesis).
The ability to probe multiple unique plasma metabolites
simultaneously with complementary analytical techniques holds
much promise for revealing altered metabolic pathways with
disease, assessing diabetic complications, and monitoring the
efficacy of therapeutic interventions.
Materials and Methods
Study Population
C-peptide negative type 1 diabetic patients (n=9) and age- and
BMI-matched non-diabetic controls (n=9) were recruited from
the local community (Olmsted County, Minnesota) and provided
written informed consent approved by the Mayo Clinic Institu-
tional Review Board and in accordance with the Declaration of
Helsinki. All study volunteers were screened with detailed medical
history, physical exam, and hematological and biochemical profile.
Potential volunteers were excluded if they exhibited renal
insufficiency, heart disease, peripheral vascular disease, neuropa-
thy, poor wound healing, or use of beta-blockers, tricyclic
antidepressants, or anticoagulants.
Study protocol
The details of this study have been published previously [13].
Type 1 diabetic subjects completed two studies; one during insulin
treatment and one during insulin deprivation with 1–2 weeks
between study days. For three days prior to each study, subjects
consumed a weight-maintaining diet (energy content as carbohy-
drate:protein:fat=55:15:30%) prepared by the Mayo CTSA
Clinical Research Unit (CRU). During the 3 days prior to the
study, subjects who were taking multiple daily insulin injections
were instructed to use ultra rapid-acting insulin before meals and
bedtime based on blood glucose concentrations. Those subjects
taking long-acting insulin were instructed to discontinue dosage for
3 days prior to the study day. Patients who used insulin pumps
were instructed to continue using ultra rapid-acting insulin until
admission to the CRU. Subjects were admitted to the CRU at
17:00 h on the evening before each study day. A standard dinner
was given at 18:00 h, after which subjects remained fasting until
the completion of the study the next day. On the insulin-treated
study day, human insulin was infused into a forearm vein to
maintain blood glucose between 4.44 and 5.56 mmol/l overnight
Metabolomics in Diabetes
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on plasma glucose levels every 30–60 minutes. On the insulin-
deprived study day, the insulin infusion was discontinued for
8.660.6h. Arterialized vanous blood was obtained from a
catheterized hand vein maintained at 60uC at 8 hours or insulin
treatment or deprivation. Plasma was kept at 280uC until analysis.
Mass spectrometry
Plasma samples and amino acid calibration standards were
prepared with MassTrak Amino Acid Analysis Solution (AAA) kit
from Waters according to instructions with slight modifications for
detection on a mass spectrometer. A 10 point standard concen-
tration curve was made from the calibration standard solution to
calculate amino acid concentrations in plasma samples. A solution
containing U-
13C4-L-aspartic acid, U-
13C3-L-alanine, U-
13C4-L-
threonine, U-
13C5-L-proline, U-
13C5-L-valine, U-
13C6-leucine,
U-
13C6-phenylalanine all from Cambridge Isotope Laboratories,
13C6-tyrosine from Isotec, L-arginine (
15N2,
2H2) from MassTrace,
norvaline from Sigma dissolved in 0.01N HCl was used as the
internal standard solution. Frozen plasma samples were thawed,
spiked with internal standard then deproteinized with cold MeOH
followed by centrifugation at 10,000 g for 5 minutes prior to
derivatization according to MassTrak instructions. The amino
acid derivatizing reagent used was 6-aminoquinolyl-N-hydroxy-
succinimidyl carbamate. High resolution separation was done
using an Acquity UPLC system, injecting 1 ml of derviatized
solution, with a UPLC BEH C18 1.7 micron 2.16150 mm
column from Waters. Column flow was set to 400 ml/min with a
gradient from 99.9%A to 98%B where buffer A is 1% acetonitrile
in 0.1% formic acid and buffer B is 100% acetonitrile. A column
temp of 43 degrees Celsius and a sample tray temp of 6% Celsius.
Mass detection was completed on a TSQ Ultra Quantum from
Thermo Finnigan running in ESI positive mode. A scan width of
0.002, scan time of 0.04 seconds per transition mass, collision
energy of 25, collision gas pressure of 1.5 mTorr, tube lens value
set to 90, monitoring a signature ion of the derivitized amines at
m/z 171.04 by selected reaction monitoring. Using this method 39
amino acids and metabolites were measured as shown in Table 2
and Table S1 (supplementary data).
1H NMR spectroscopy
Frozen plasma samples were thawed and 500 mlw a sm i x e d
with phosphate buffer (75 ml, 0.5M, pH 7.0), D2O( 7 5ml), 3-
(Trimethylsilyl)propionic acid-d4 sodium salt (TSP, 5mli nD 2O,
12.3 nmol). Any particulate matter was removed by centrifuga-
tion and 500 ml of the supernatant was transferred into 5-mm
NMR tubes. All high-resolution
1H NMR experiments on
plasma were performed at 25uCo naB r u k e rD R X5 0 0
spectrometer equipped with a HCN triple resonance cryogenic
probehead.
1H NMR spectra were acquired using the Carr-
Purcell-Meiboom-Gill (CPMG) experiment with water presatu-
ration. CPMG experiments are useful for the analysis of plasma
to reduce the contribution of broad and mostly featureless
protein signals. Each dataset was averaged over 32 transients
using 32K time domain points. The data were Fourier
transformed after multiplying by an exponential window
function with a line broadening of 0.3 Hz, and the spectra
were phase and baseline corrected using the Bruker XWinNMR
software version 3.5. Twenty plasma metabolites were identified
based on their characteristic chemical shifts and multiplicities
and quantified by integrating peak areas relative to a reference
signal from 3-(Trimethylsilyl)propionic acid-d4 sodium salt
(TSP). The NMR assignments were made based on literature
values, and tentative assignments made due to the overlap or
slight shift in their positions were confirmed by re-recording 1H
NMR spectra for before and after the addition of small
quantities of the respective standard compounds.
Statistical Analysis
Each NMR data set was binned to 4096 points (bin
size=0.003 ppm) to minimize the effects of pH and ionic
concentrations. The data were aligned with reference to the
TSP signal and the regions containing TSP, urea and residual
water (4.6,5.3 ppm) signals were removed. The NMR data were
mean-centered and then subjected to unsupervised statistical
analysis, PCA, using Pirouette software version 3.11 (Infometrix
Inc., PA) to classify the samples (control or diabetic) based on the
metabolites that varied the most across the entire sample set.
Individual plasma metabolites determined by
1H NMR spectros-
copy and plasma amino acids determined by UPLC-MS/MS were
compared across diabetic and control subjects by unpaired t-tests
and in treated vs. untreated diabetic subjects by paired t-tests. P
values for individual metabolites were determined by the standard
t-test. A Benjamini–Hochberg correction was applied to adjust the
P values by accounting for the multiple metabolites used in the
analysis. In addition, the Pearson correlations among all the
metabolites (for insulin-deprive, treated and control samples
separately) were calculated utilizing the R software package. The
statistical significance of the correlation coefficients was tested
using a t test by giving a null hypothesis (H0) of r=0, where r
represents the correlation coefficient. If H0 holds, t~
r
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
n{2
p
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1{r2
p
approximately follows the t distribution with degrees of freedom
equal to n–2, where n represents the sample size. A low P value
(,0.05) for this test means that there is evidence to reject the null
hypothesis in favor of the alternative hypothesis or that there is a
statistically significant relationship between the two variables
(metabolites). Correspondingly, an absolute value of r larger than
0.76 is considered as a statistically significant relationship between
the two metabolites.
Supporting Information
Figure S1 Representative Chromatograms for plasma metabo-
lites measured by LC-MS/MS. Example chromatograms of 41
analytes in plasma from a type 1 diabetic patient treated with
insulin (top), deprived of insulin (middle), and a non-diabetic
control subject (bottom).
Found at: doi:10.1371/journal.pone.0010538.s001 (0.37 MB TIF)
Figure S2 Representative 1H-NMR spectra of plasma metab-
olites. Representative 1H-NMR spectra of plasma from an insulin
treated type 1 diabetic patient (top), and insulin deprived type 1
diabetic patient (middle), and a non-diabetic control subject
(bottom). Identified metabolites: 1, allantoin; 2, acetate; 3, acetone;
4, 3-hydroxybutyrate ; 5, acetoacetate; 6, valine; 7, lactate; 8,
alanine; 9, tyrosine; 10, citrate; 11, histidine; 12, formate; 13,
creatinine; 14, glycoprotein N-acetyl groups; 15, lipid:CH3; 16,
lipid:CH2; 17, lipid:CH2CH2-CO;18, lipid:CH2-C=C;19, Li-
pid:fatty acyl groups=CH; 20: Glucose.
Found at: doi:10.1371/journal.pone.0010538.s002 (1.43 MB TIF)
Table S1 Interassay variation for plasma amino acid metabolites
measured by LC-MS/MS. Interassay variation of the plasma amino
acid and metabolite measurements by LC-MS/MS using the
Masstrak reagents. A total of 19 replicates were measured over the
course of a 1 month period using a plasma quality control sample.
Found at: doi:10.1371/journal.pone.0010538.s003 (0.06 MB
DOC)
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